Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone-Dexborneol Sublingual Tablets for Prevention of Post-Stroke Cognitive Impairment After Acute Ischemic Stroke
CTR20240862Phase 2Active
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of edaravone and dexborneol in confusion (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Safety events, Treatment discontinuation or withdrawal and 1 more. Started Apr 2024; status: active.
02
Drugs
edaravonedexborneol
03
Conditions
confusion
Beyond the preview
Go deeper on CTR20240862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240862.